Navigation Links
Surveyed European Oncologists Assign Greater Patient Share to Johnson & Johnson's Abiraterone Compared With Other Emerging Therapies in Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Date:9/30/2010

tant prostate cancer (NMCRPC), Amgen's Prolia has considerable commercial potential assuming it can gain approval as an anti-neoplastic agent (and improve bone metastases-free survival). Significant commercial potential in the NMCRPC setting arises from the large drug-treatable pool and potentially long treatment durations.

The report also finds that abiraterone use in the asymptomatic setting is the only emerging therapy in NMCRPC or first-line MCRPC which is likely to secure a favorable NICE appraisal, according to the majority of surveyed oncologists in the United Kingdom. Interviewed payers indicate that the premium prices of emerging therapies, (notably Revlimid and Provenge) may limit uptake although generic docetaxel will help stimulate use of emerging therapies used in combination with docetaxel because of an overall reduced cost of the regimen.

The report is based on a survey of 251 oncologists from Germany (50), France (50), Italy (51), Spain (50) and the United Kingdom (50) and interviews with 15 European payers from Germany (3), France (3), Italy (3), Spain (3) and the United Kingdom (3).

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or regis
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
2. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
3. Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections
4. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
5. Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer
6. Majority of Surveyed Pharmacy Directors Expect To Cover Pfizers Tanezumab If It Is Approved for the Treatment of Chronic Pain
7. An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists
8. In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1
9. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
10. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... DIEGO , Sept. 30, 2014 ... three-dimensional biology company focused on delivering breakthrough 3D ... Liver Model has been selected as a finalist in ... 2014 Most Innovative New Product Awards, sponsored by ... of innovative technology and life sciences products in ...
(Date:9/30/2014)... -- The Corporate Whistleblower Center is urging ER doctors, ... if they have well documented proof of a ... sent home, as an intentional way to overbill ... the Center would like to explain. http://CorporateWhistleblowerCenter.Com ... Photo - http://photos.prnewswire.com/prnh/20140929/149017 ...
(Date:9/30/2014)... EXECUTIVE SUMMARY The present report ... - Increasing Demand from Ageing Population to Drive ... past, present and future outlook. The report discusses ... market with outlook to 2017. Statistics include functional ... sub-segments of the industry, ongoing trends and developments, ...
Breaking Medicine Technology:Organovo Inc. Selected As A Finalist In 27th Annual CONNECT Most Innovative New Product Awards 2Organovo Inc. Selected As A Finalist In 27th Annual CONNECT Most Innovative New Product Awards 3Corporate Whistleblower Center Urges ER Doctors or Nurse Managers to Call Them if They Have Proof of a Hospital Needlessly Admitting Medicare Patients Instead of Sending Them Home 2Corporate Whistleblower Center Urges ER Doctors or Nurse Managers to Call Them if They Have Proof of a Hospital Needlessly Admitting Medicare Patients Instead of Sending Them Home 3Corporate Whistleblower Center Urges ER Doctors or Nurse Managers to Call Them if They Have Proof of a Hospital Needlessly Admitting Medicare Patients Instead of Sending Them Home 4North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 2North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 3
(Date:9/30/2014)... Fla. (PRWEB) September 30, 2014 Lea ... is giving breast cancer patients a new, more practical ... , Women who undergo mastectomies, biopsies and lumpectomy surgeries ... promote healing. But after seeing her patients describe the ... compelled to create a new bra in her spare ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 AxoGen, ... focused on the peripheral nerve repair market, announced the ... during the American Society for Surgery of the Hand ... in Boston. , The ASSH Best ... Utilization of Processed Nerve Allografts for Large Gap Nerve ...
(Date:9/30/2014)... Brig Hart, one of the most ... 500 Diamond-ranked professionals using his systematic way of building ... The Life Support System for Ultimate Success , founded ... using his experiences and successes over the past 30 ... and methodology taught by Brig in this system, Mick ...
(Date:9/30/2014)... 30, 2014 During this online ... approaches to health including achieving hormonal balance, relieving ... and detoxification. , The details ... Date: October 6-9, 2014, Location: Online Event, Registration: ... http://www2.hotzehwc.com/naturalhealthsummitregistration , Monday, October 6th, Steven F. ...
(Date:9/30/2014)... 2014 Timber Home Living Magazine is documenting ... Olsen family’s reclaimed Douglas fir timber frame home in Austerlitz, ... from architectural planning, to the frame raising, to enclosure, to ... Energy Works, after following the timber framing company for years ... dream vacation home on land they fell in love with ...
Breaking Medicine News(10 mins):Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 4Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 5Health News:Brig Hart Announces the First Diamond Elite Representatives using his Life Support System 2Health News:Brig Hart Announces the First Diamond Elite Representatives using his Life Support System 3Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 2Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 3
... one of the most lethal cancers, with fewer than five ... new study that peers deeply into the genetics of pancreatic ... early diagnosis. In contrast to earlier predictions, many pancreatic tumors ... become lethal after the first genetic perturbations appear. "There ...
... People who regularly eat whole grains rather than refined grains ... a higher risk for heart disease and type 2 diabetes, ... (VAT) -- the fat that surrounds the intra-abdominal organs -- ... cholesterol and insulin resistance, health risk factors collectively known as ...
... , TUESDAY, Oct. 26 (HealthDay News) -- As many ... if people followed five simple healthy lifestyle recommendations, Danish ... overall health as well -- include exercise, a good ... weight, the researchers say. "Even a modest difference ...
... University and University of North Carolina (UNC) researchers report ... Research that narcotics and diagnostic testing are overused ... may overlook more effective treatments for neck pain, such ... study, evidence to support the effectiveness of therapeutic exercise ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Oct. 26 ... the blood-thinning drug Plavix (clopidogrel) may be at increased risk ... finds. Having the gene variants seems to reduce the ... developing blood clots in the stent, suffering a heart attack ...
... -- Children who survive cancer face an increased risk ... The findings highlight the increased need for long-term ... researchers said. "Current treatments have dramatically increased survival ... many cancer therapies -- including surgery, radiation, and chemotherapy ...
Cached Medicine News:Health News:Revising the timeline for deadly pancreatic cancer 2Health News:Revising the timeline for deadly pancreatic cancer 3Health News:Eating Whole Grains, Fewer Refined Grains, May Help Heart 2Health News: Healthy Living Can Prevent Nearly 25% of Colorectal Cancers 2Health News: Healthy Living Can Prevent Nearly 25% of Colorectal Cancers 3Health News:Narcotics and diagnostics overused in treatment of chronic neck pain 2Health News:Gene Mutations May Blunt Plavix's Effectiveness, Study Finds 2Health News:Gene Mutations May Blunt Plavix's Effectiveness, Study Finds 3Health News:Childhood Cancer Survivors Risk Future GI Problems 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: